AUPH

AUPH

USD

Aurinia Pharmaceuticals Inc Ordinary Shares

$8.180+0.130 (1.615%)

Reaalajas hind

Healthcare
Biotehnoloogia
Kanada

Hinnagraafik

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$8.050

Kõrge

$8.210

Madal

$7.970

Maht

0.33M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.1B

Tööstusharu

Biotehnoloogia

Riik

Canada

Kauplemisstatistika

Keskmine maht

1.40M

Börs

NGM

Valuuta

USD

52 nädala vahemik

Madal $4.92Praegune $8.180Kõrge $10.67

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 26. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

AUPH: Aurinia Pharmaceuticals Inc Ordinary Shares - Checking the Pulse and What the Data Hints At

Stock Symbol: AUPH Generate Date: 2025-04-26 12:04:19

Alright, let's take a look at what's been going on with Aurinia Pharmaceuticals, ticker symbol AUPH. We've got some recent history, a bit of news, and even an AI's take on the next couple of days.

What's Been Happening? The News and the Price Tag

The main news item we have here is from back in February. Aurinia announced they'd be dropping their 2024 financial results on February 27th. Now, that news itself isn't good or bad – it's just letting everyone know when the report is coming out. But these financial reports are a big deal because they show how the company actually performed.

Looking at the stock price chart for the last few months, you can see that date, February 27th, stands out. The price took a pretty sharp dive right around then. Before that, the stock was trading mostly in the $7.80 to $8.30 range. After the earnings report came out, it dipped significantly, even touching the mid-$6 range briefly.

Since that earnings dip, the price has been quite volatile. It bounced back up into the $7s and $8s in March, even hitting a high around $8.85. Then it drifted lower again through late March and early April, finding a bottom around $7.00-$7.20. More recently, over the last couple of weeks in April, the stock has been climbing back up, getting back into the $8 range where it sits now. So, it's been a bit of a rollercoaster ride since that earnings announcement.

What the AI Sees Coming

We also have a peek at what an AI model predicts for the very near future. For today, it sees basically no change (0.00%). But for the next two days, it predicts small increases: 0.85% the first day and 1.91% the day after that. This suggests the AI thinks the recent upward nudge might continue just a little bit.

Putting It Together: What Does This Suggest?

Based on the recent price action – specifically the recovery from the early April lows – and the AI's forecast for slight near-term gains, the current situation might lean slightly positive for the very short term. The stock has shown it can recover after dips, and the AI seems to agree that the immediate trend is upward, albeit modestly.

Now, thinking about potential moves:

  • If you're considering getting in: The stock is currently trading around the $8 mark. The recommendation data points to a support level near $8.05, which is right in this neighborhood. If you're comfortable with the volatility this stock has shown, this area could be a point to watch for a potential entry, aligning with the recent bounce and the AI's slight positive outlook.
  • If you're already holding or thinking about managing risk: The recommendation data suggests a stop-loss around $7.27. This level makes sense because it's below the recent lows we saw in early April. If the price were to fall below there, it could signal that the recent recovery is failing. For taking profits, the AI only predicts small near-term gains. The recommendation data mentions a take-profit at $8.24, which is very close to the current price and the AI's predicted movement. Longer-term analyst targets are higher (around $9.83), but that's a different timeframe than the immediate AI prediction.

Keep in mind, this stock has a history of big swings, especially around company news like earnings reports. While the AI sees a small bump ahead, the overall picture includes that sharp drop we saw in February.

A Little About Aurinia

Just to add some context, Aurinia is a biotechnology company. They focus on developing treatments for autoimmune diseases, like lupus nephritis. Biotech stocks can often be quite sensitive to news about their drug trials, regulatory approvals, and sales performance. They can also have high valuations relative to their earnings (the recommendation data flagged a high P/E ratio), which can sometimes add to their volatility.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are inherently risky, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

BusinessWire

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27,

Vaata rohkem
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 28. apr 2025, 06:50

LangevNeutraalneTõusev

68.4% Kindlus

Risk ja kauplemine

Riskitase3/5
Keskmine risk
Sobib
Kasv
Kauplemisjuhend

Sisenemispunkt

$8.16

Võta kasum

$8.69

Peata kahjum

$7.37

Põhitegurid

PDI 9.1 on MDI 6.1 kohal ADX-iga 11.9, mis viitab tõusutrendile
Praegune hind on tugitasemele ($8.16) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 4.2x keskmisest (15,772), mis viitab äärmiselt tugevale ostusurvele
MACD -0.0013 on signaalijoone -0.0026 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.